Close Menu

NEW YORK – KDx Diagnostics announced late on Tuesday that it has received the CE mark for its urine-based URO17 Bladder Cancer Recurrence test for bladder cancer.

As a result, the test can be marketed in Europe and other countries that recognize the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.